EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Xencor's enterprise value is $780.6 Mil.
Xencor's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $168.3 Mil. Therefore, Xencor's EV-to-Revenue for today is 4.64.
The historical rank and industry rank for Xencor's EV-to-Revenue or its related term are showing as below:
XNCR'
s EV-to-Revenue Range Over the Past 10 Years
Min: 2.75 Med: 14 Max: 102.17
Current: 4.61
During the past 13 years, the highest EV-to-Revenue of Xencor was 102.17. The lowest was 2.75. And the median was 14.00.
XNCR's EV-to-Revenue is ranked better than 62.56% of 1031
companies
in the Biotechnology industry
Industry Median: 7.91
vs XNCR: 4.61
As of today (2024-05-02), Xencor's stock price is $23.93.
Xencor's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.79. Therefore, Xencor's PS Ratio for today is 8.58.
Xencor EV-to-Revenue Historical Data
The historical data trend for Xencor's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Xencor's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xencor's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xencor's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Xencor's EV-to-Revenue falls into.
Xencor's current Enterprise Value is $780.6 Mil.
Xencor's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $168.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor's share price for today is $23.93.
Xencor's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.79.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xencor EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Xencor's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XNCR has been successfully added to your 